Cas:5417-80-1 6-chloro-4-ethylsulfanyl-1H-pyrazolo[3,4-d]pyrimidine manufacturer & supplier

We serve Chemical Name:6-chloro-4-ethylsulfanyl-1H-pyrazolo[3,4-d]pyrimidine CAS:5417-80-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-chloro-4-ethylsulfanyl-1H-pyrazolo[3,4-d]pyrimidine

Chemical Name:6-chloro-4-ethylsulfanyl-1H-pyrazolo[3,4-d]pyrimidine
CAS.NO:5417-80-1
Synonyms:6-chloro-4-(ethylsulfanyl)-1h-pyrazolo[3,4-d]pyrimidine;4-ethylmercapto-6-chloro-1(2)H-pyrazolo[3,4-d]pyrimidine;4-Aethylmercapto-6-chlor-1(2)H-pyrazolo[3,4-d]pyrimidin
Molecular Formula:C7H7ClN4S
Molecular Weight:214.67500
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:368.2ºC at 760 mmHg
Density:1.52g/cm3
Index of Refraction:1.69
PSA:79.76000
Exact Mass:214.00800
LogP:2.11830

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 6-chloro-4-(ethylsulfanyl)-1h-pyrazolo[3,4-d]pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Aethylmercapto-6-chlor-1(2)H-pyrazolo[3,4-d]pyrimidin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-chloro-4-(ethylsulfanyl)-1h-pyrazolo[3,4-d]pyrimidine Use and application,4-Aethylmercapto-6-chlor-1(2)H-pyrazolo[3,4-d]pyrimidin technical grade,usp/ep/jp grade.


Related News: The therapy is designed to treat ADA-SCID, a genetic condition in which children are born without a properly functioning immune system. Fmoc-D-Phe(4-CN)-OH manufacturers Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. DL-Homophenylalanine methyl ester hydrochloride suppliers Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments. 2-methyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanenitrile vendor & factory.